NanoViricides Inc. (NNVC)

[Ubertino]

Tried that link - 'Content not avalable' - so I Googled 'Ken S Rosenthal' and he looks like a pretty sharp cookie:

NanoViricides Announces a Herpes Virus Research Agreement With Professor Ken S. Rosenthal of Northeastern Ohio Universities College of Medicine

NanoViricides Inc.Posted on:13 May 10

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal’s laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

Under this agreement, Dr. Rosenthal and coworkers will evaluate the effectiveness of nanoviricides® drug candidates against Herpes simplex virus 1 (HSV-1). Cell culture models as well as in vivo (animal) studies will be employed for testing the drug candidates. This testing is expected to help the Company develop an effective nanoviricide drug against oral and genital herpes.

Dr. Rosenthal has been involved in the evaluation of HSV vaccines as well as anti-HSV drugs. His laboratory has developed an improved mouse model of skin-infection with HSV to follow the disease progression. This model has been shown to provide highly uniform and reproducible results. A uniform disease pattern including onset of lesions and further progression to zosteriform lesions is observed in all animals in this model. This uniformity makes it an ideal model for comparative testing of various drug candidates which, the Company believes, can be expected to lead to a broad-spectrum anti-HSV antiviral treatment capable of attacking both HSV-1 and HSV-2.

Dr. Rosenthal is a professor of microbiology, immunology and biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM). He is a leading researcher in the field of herpes viruses. His research interests encompass several aspects of how herpes simplex virus (HSV) interacts with the host to cause disease. His research has addressed how HSV infects skin cells and examined viral properties that facilitate its virulence and ability to cause encephalitis. In addition, Dr. Rosenthal has also been studying a viral protein that makes the HSV more virulent by helping the virus to take over the cellular machinery to make copies of its various parts, assemble these parts together into virus particles and release the virus to infect other cells. He is also researching how the human host immune response works against HSV for the development of protective and therapeutic vaccines.

The Company has developed a library of small chemical ligands that bind to the herpes virus envelope proteins. Using these ligands, a number of candidate nanoviricides that are capable of attacking the herpes virus have been developed. The Company believes that these nanoviricide drug candidates mimic the natural, common attachment function by which HSV-1 and HSV-2 bind to the body’s host cells.

The Company has previously reported that some of our nanoviricide anti-HSV drug candidates reduced HSV viral load by as much as 99.99% in certain cell culture studies.

“We are very excited about this association with the Rosenthal Lab,” said Dr. Eugene Seymour, MD, MPH, CEO of the Company, adding, “We will now be able to rapidly evaluate our anti-herpes therapeutics.”

About NEOUCOM

The Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) is a community-based, public institution focused on the interprofessional training of health professionals. Through its educational, research and service mission, NEOUCOM improves the quality of health care in northeast Ohio. The University is a member of the university system of Ohio and its partners include teaching hospitals, community sites and boards of health.

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=21777

Would appreciate a follow up on a regular basis on this and ALL other investigators!!

Search Results

There are 3 results for: "Ken S. Rosenthal" in Author

1.
Amphiphilic membranes with controlled mesh dimensions for insulin delivery+
Macromolecular Symposia

Volume 172, Issue 1, July 2001, Pages: 56–66, Joseph P. Kennedy, Gyorgyi Fenyvesi, Richard P. Levy and Ken S. Rosenthal

Article first published online : 30 AUG 2001, DOI: 10.1002/1521-3900(200107)172:1<56::AID-MASY56>3.0.CO;2-D
* Abstract
* PDF(1531K)
http://is.gd/gfXBG
2.
You have full text access to this OnlineOpen article
Flow cytometric evaluation of anti-herpes drugs†
Cytometry

Volume 8, Issue 4, July 1987, Pages: 392–395, Ken S. Rosenthal, Cheryl M. Hodnichak and Jack L. Summers

Article first published online : 8 MAR 2005, DOI: 10.1002/cyto.990080408
* Abstract
* PDF(375K)
* References
http://is.gd/gfXIg
3.
Cell membrane potential changes follow epstein-barr virus binding
Journal of Cellular Physiology

Volume 117, Issue 1, October 1983, Pages: 39–42, Ken S. Rosenthal and Howard M. Shapiro

Article first published online : 4 FEB 2005, DOI: 10.1002/jcp.1041170107
* Abstract
* PDF(513K)
* References
http://is.gd/gfXL8


If NNVC is a scam - I can't see it. Course I'm not as bright a light as some around here - been called a moron and worse by one unnamed expert!!! Hope to see $2+ again real soon. If NNVC is a scam - I'll eat my ligand!